Roche announced today that the U.S. Food and Drug Administration (FDA) has approved Mircera (methoxy polyethylene glycol-epoetin beta) for the treatment of anaemia associated with chronic kidney ...

A big plus for Roche today after the European Commission issued a final positive decision for its once- or twice-monthly anaemia drug Mircera for use in chronic kidney disease patients that is valid ...

New data for Roche’s anaemia drug Mircera confirm that the drug can raise haemoglobin levels in the blood with twice-monthly dosing, suggesting it will mount a strong challenge to current treatments ...

The approval was based on an open-label, multiple dose, multicenter, dose-finding study in 64 pediatric patients with CKD who were on hemodialysis and who had stable hemoglobin levels while previously ...